Cargando…
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design
OBJECTIVES: This study will compare the incidence of major adverse cardiovascular events (MACEs) with androgen deprivation therapy (ADT) among men with advanced prostate cancer who are being treated with a gonadotropin-releasing hormone (GnRH) antagonist versus a GnRH agonist. BACKGROUND: Treatment...
Autores principales: | Melloni, Chiara, Slovin, Susan F., Blemings, Allan, Goodman, Shaun G., Evans, Christopher P., Nilsson, Jan, Bhatt, Deepak L., Zubovskiy, Konstantin, Olesen, Tine K., Dugi, Klaus, Clarke, Noel W., Higano, Celestia S., Roe, Matthew T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352040/ https://www.ncbi.nlm.nih.gov/pubmed/34396210 http://dx.doi.org/10.1016/j.jaccao.2020.01.004 |
Ejemplares similares
-
Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer
por: Lazenby, Mark
Publicado: (2012) -
Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
por: Wallach, Joshua D., et al.
Publicado: (2021) -
Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety
por: Merola, David, et al.
Publicado: (2022) -
Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review
por: Nelson, Adam J., et al.
Publicado: (2023) -
Evaluation of degarelix in the management of prostate cancer
por: Van Poppel, Hendrik
Publicado: (2010)